A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Idiopathic Urticaria
Chronic Idiopathic Pruritus
Lichen Planus
Lichen Simplex Chronicus
Plaque Psoriasis

Interventions

DRUG: KPL-716
DRUG: Placebo

Sponsor

Genentech, Inc.

Collaborators

[object Object]